Vaxart, Inc. (VXRT): Nasdaq/NYSE listing notice — Vaxart receives Nasdaq delisting notice for failure to maintain $1 minimum bid price

Vaxart, Inc.

Received Nasdaq notice on July 21, 2023 for non-compliance with $1.00 minimum bid price rule.
Closing bid price below $1.00 for 30 consecutive business days from June 7 to July 20, 2023.
Has 180 calendar days, until January 17, 2024, to regain compliance by closing at $1.00+ for 10 consecutive days.
If not cured, may be eligible for additional 180-day period if it meets other listing requirements and considers reverse stock split.
Company states it is actively monitoring and evaluating options to regain compliance.

item 3.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

Vaxart, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

July 21, 2023, Vaxart, Inc. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 Minimum Bid Price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”). The Notice does not result in the immediate delisting of the Company’s common stock from The Nasdaq Capital Market. The Nasdaq Listing Rules require listed securities to maintain a minimum bid price of $1.00 per sh

View on SEC.gov

Browse all listing & compliance notices →

Vaxart, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-23-020716

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.